$5.24 Million in Sales Expected for Celularity Inc. (NASDAQ:CELU) This Quarter

Equities analysts expect Celularity Inc. (NASDAQ:CELUGet Rating) to post $5.24 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Celularity’s earnings, with the highest sales estimate coming in at $7.48 million and the lowest estimate coming in at $2.75 million. Celularity posted sales of $3.20 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 63.8%. The business is scheduled to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Celularity will report full year sales of $20.50 million for the current financial year, with estimates ranging from $11.00 million to $27.81 million. For the next financial year, analysts expect that the company will post sales of $20.97 million, with estimates ranging from $11.00 million to $29.20 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Celularity.

Celularity (NASDAQ:CELUGet Rating) last announced its quarterly earnings data on Thursday, March 31st. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.28.

A number of research analysts recently weighed in on CELU shares. Truist Financial lowered Celularity from a “buy” rating to a “hold” rating and set a $10.00 price objective on the stock. in a report on Wednesday, April 6th. Oppenheimer upped their price objective on Celularity from $9.00 to $10.00 in a report on Friday, April 1st. Finally, Zacks Investment Research downgraded Celularity from a “buy” rating to a “hold” rating in a research report on Monday, April 4th.

A number of institutional investors and hedge funds have recently bought and sold shares of CELU. Jane Street Group LLC boosted its stake in shares of Celularity by 28.3% during the first quarter. Jane Street Group LLC now owns 16,813 shares of the company’s stock valued at $146,000 after acquiring an additional 3,713 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Celularity during the first quarter valued at $181,000. Citigroup Inc. acquired a new stake in shares of Celularity during the first quarter valued at $36,000. Starr International Co. Inc. boosted its stake in shares of Celularity by 76.9% during the first quarter. Starr International Co. Inc. now owns 15,281,389 shares of the company’s stock valued at $133,101,000 after acquiring an additional 6,640,694 shares during the last quarter. Finally, C V Starr & Co. Inc. boosted its stake in shares of Celularity by 76.9% during the first quarter. C V Starr & Co. Inc. now owns 7,640,693 shares of the company’s stock valued at $66,550,000 after acquiring an additional 3,320,346 shares during the last quarter. Institutional investors own 12.13% of the company’s stock.

Shares of CELU stock opened at $7.56 on Wednesday. The business’s fifty day moving average price is $9.26 and its 200 day moving average price is $6.96. Celularity has a 1-year low of $3.63 and a 1-year high of $13.40. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.28.

About Celularity (Get Rating)

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase 1 clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase 1 clinical trial to treat acute myeloid leukemia, as well as in Phase 1/2a clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase 1 clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.

Featured Articles

Get a free copy of the Zacks research report on Celularity (CELU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.